search icon

    Market Snapshot

    • S&P Futures

      3,914.75

    • Dow Futures

      31,478

    • Nasdaq Futures

      12,132.75

    blog search icon

    Innate Pharma S.A.

    (NASDAQ:IPHA)

    $2.62

    $0.00

    -

    Innate Pharma S.A. Chart

    IPHA Stock Price Today

    Innate Pharma S.A. (IPHA) stock declined over - intraday to trade at $2.62 a share on NASDAQ. The stock opened with a loss of -0.76% at $2.65 and touched an intraday high of $2.73, rising 0.00% against the last close of $2.62. The stock went to a low of $2.62 during the session.

    Stock Snapshot

    $2.62

    Prev. Close

    258.46 Million

    Market Cap

    $2.62

    Day Low

    $2.65

    Open

    98.65 Million

    Number of Shares

    $2.73

    Day High

    -

    P/E ratio

    -0.60

    EPS (TTM)

    1.51

    Cash Flow per Share

    0.20

    Free Float in %

    1.69

    Book Value

    20,890

    Volume

    Innate Pharma S.A. Historical Data

    DateOpenHighLowCloseVolume
    2022-06-23$2.65$2.73$2.62$2.6220,900
    2022-06-22$2.64$2.72$2.62$2.6252,800
    2022-06-21$2.56$2.83$2.51$2.68311,600
    2022-06-17$2.44$2.514$2$2173,400
    2022-06-16$2.49$2.49$2.3$2.34157,200
    2022-06-15$2.521$2.56$2.5$2.534,400
    2022-06-14$2.57$2.58$2.5$2.5710,000
    2022-06-13$2.66$2.67$2.57$2.6421,000
    2022-06-10$2.87$2.87$2.67$2.878,900
    2022-06-09$3.03$3.03$2.99$3700

    Contact Details

    117, Avenue de Luminy
    BP 30191
    Marseille 13009
    France

    Webiste:IPHA

    33 4 30 30 30 30

    Company Information

    Employees-

    Beta-

    Sales or Revenue24.7 Million

    5Y Sales Change-

    Fiscal Year Ends2021-12-30

    SectorHealth Care

    IndustryBiotechnology

    About Company

    Innate Pharma S.A., a biotechnology company, discovers, develops, and commercializes therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sezary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; Avdoralimab (IPH5401), a monoclonal antibody blocking C5a binding to C5aR1 that is in Phase II clinicals trials for the treatment of COVID-19, bullous pemphigoid, chronic spontaneous urticaria, and other inflammatory diseases; IPH5201, a blocking antibody that is in Phase 1 clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; and IPH6101, a NKp46-based NK cell engager for the generation and evaluation of up to two bispecific NK cell engagers. Its products in preclinical trials are IPH43, an anti-MICA/B antibody drug conjugate; Anti-Siglec-9, an antibody program; IPH65, a tetraspecific proprietary antibody; IPH25, a checkpoint inhibitor; and IPH62 and IPH64 programs. Innate Pharma S.A. has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. The company was incorporated in 1999 and is headquartered in Marseille, France.

    Frequently Asked Questions

    icon

    What is the current Innate Pharma S.A. (IPHA) stock price?

    Innate Pharma S.A. (NASDAQ: IPHA) stock price is $2.62 as of the last check on Thursday, June 23. During the trading session, IPHA stock reached the peak price of $2.73 while $2.62 was the lowest point it dropped to.

    icon

    IPHA's industry and sector of operation?

    The NASDAQ listed IPHA is part of Biotechnology industry that operates in the broader Health Care sector. Innate Pharma S. A.

    icon

    Who are the executives of IPHA?

    Ms. Laure-Helene Mercier M.B.A., M.Sc., MSc, MBA
    Exec. VP of Fin. & Corp. Strategy
    Dr. Mondher Mahjoubi M.D.
    Chairman of Exec. Board & CEO
    Mr. Yannis Morel Ph.D.
    Exec. VP of Product Portfolio Strategy & Bus. Devel. and Member of Exec. Board
    Dr. Herve Brailly
    Co-Founder & Chairman of Supervisory Board

    icon

    What is the IPHA stock price today?

    IPHA stock traded closed the last session at $2.62, which is $0.00 or - lower than its previous close of $2.62. IPHA's current trading price is 31.00% lower than its 52-week high of $11.95 where as its distance from 52-week low of 2.00% is -78.08%.

    icon

    How many employees does IPHA have?

    Number of IPHA employees currently stands at -. IPHA operates from 117, Avenue de Luminy, BP 30191, Marseille 13009, France.

    icon

    Link for IPHA official website?

    Official Webiste of $IPHA is: https://www.innate-pharma.com

    icon

    How do I contact IPHA?

    IPHA could be contacted at IPHA operates from 117, Avenue de Luminy, BP 30191, Marseille 13009, France, or at phone #33 4 30 30 30 30 and can also be accessed through its website.

    icon

    How many shares of IPHA are traded daily?

    IPHA stock volume for the day was 20,890 shares while in the previous session number of IPHA shares traded was 20,900 . The average number of IPHA shares traded daily for last 3 months was 26.45 Thousands.

    icon

    How much did IPHA change today?

    The percentage change in IPHA stock occurred in the recent session was - while the dollar amount for the price change in IPHA stock was $0.00.

    icon

    What price range IPHA stock been trading in?

    In the recent session, the day high for IPHA stock was $2.73 while the low for IPHA stock touched on the day was $2.62.

    icon

    What is the market cap of IPHA currently?

    The market value of IPHA currently stands at 258.46 Million with its latest stock price at $2.62 and 98.65 Million of its shares outstanding.